M. Rassool

发表

Prevalence of peripheral neuropathy in antiretroviral therapy naïve HIV-positive patients and the impact on treatment outcomes—a retrospective study from a large urban cohort in Johannesburg, South Africa

M. Maskew, D. Evans, S. Takuva, 2012, Journal of NeuroVirology.

Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial.

M. Lederman, L. Montaner, S. Ellenberg, 2014, The lancet. HIV.

Antiretroviral therapy in HIV‐1‐infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation

L. Montaner, L. Azzoni, I. Sanne, 2016, Journal of leukocyte biology.

Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/μl is associated with improved treatment outcomes in South Africa

R. Wood, C. Orrell, M. Dehlinger, 2010, AIDS.

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

P. Sax, K. Squires, P. Cahn, 2018, Journal of acquired immune deficiency syndromes.

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS Study.

M. Lederman, L. Montaner, S. Ellenberg, 2014, The lancet. HIV.

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

A. Crook, A. Diacon, K. Reither, 2019, The Lancet. Respiratory medicine.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Nurse management is not inferior to doctor management of antiretroviral patients: The CIPRA South Africa randomised trial

R. Wood, C. Orrell, M. Dehlinger, 2011 .

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial

G. Churchyard, K. Fielding, R. Wallis, 2021, The Lancet. Respiratory medicine.

Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial

M. Lederman, L. Azzoni, B. Rodriguez, 2017, Pathogens & immunity.

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial

G. Churchyard, K. Fielding, R. Wallis, 2022, PloS one.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

C. Katlama, P. Sax, Y. Yazdanpanah, 2017, The lancet. HIV.

Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update

G. Maartens, M. Moorhouse, W. Preiser, 2020, Southern African journal of HIV medicine.

Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine

A. Winston, H. Teppler, Valerie Teal, 2020, AIDS.

Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial

R. Wood, C. Orrell, M. Dehlinger, 2010, The Lancet.

Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.

M. Reitsma, J. Mellors, R. Kantor, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults

Y. Manabe, M. Hosseinipour, J. Kumwenda, 2017, AIDS.

Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.

Yongwu Shao, D. Porter, D. SenGupta, 2016, The lancet. HIV.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

M. Maskew, D. Evans, S. Takuva, 2012, Journal of NeuroVirology.

Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.

A. Mocroft, H. Furrer, A. Clarke, 2017, International journal of antimicrobial agents.

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

A. Rachow, O. Owolabi, M. Rassool, 2022, International journal of environmental research and public health.

Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial

M. Hughes, R. Schooley, J. Mellors, 2012, PLoS medicine.

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.

T. McHugh, I. Motta, M. Spigelman, 2022, The New England journal of medicine.

The lived experiences of Tuberculosis survivors during the COVID-19 pandemic and government lockdown in South Africa: a qualitative analysis

M. Rassool, A. Moolla, Constance Mongwenyana, 2023, Research square.

A randomized clinical trial comparing metabolic parameters after 48 weeks of standard‐ and low‐dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV‐infected South African patients

F. Raal, I. Sanne, M. Rassool, 2014, HIV medicine.

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

L. Rigouts, K. Sanders, M. Gurumurthy, 2022, The Lancet.

Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy

S. Sweeney, N. Kitson, M. Rassool, 2020, BMJ Open.

Efficacy, safety and CNS effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine in a randomized controlled trial.

A. Winston, H. Teppler, Valerie Teal, 2021, AIDS.

Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update

G. Maartens, M. Moorhouse, W. Preiser, 2020, Southern African journal of HIV medicine.

Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.

M. Reitsma, J. Mellors, R. Kantor, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.